Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Pragmatiston Feb 19, 2021 6:31pm
159 Views
Post# 32616428

RE:Shelf Supplement

RE:Shelf Supplement
Pragmatist wrote: The supplement isnow available on Sedar;  The price to the public is $6.

 "NOTES: (1) The Offering Price was determined by negotiation between the Company and the Underwriters, with reference to the then-current market price of the Common Share"


The price was likely determined before the recent escalation.  It sounds like a good deal. for ATE..

My understaning based on research last PO, is that underwriters and their officers are not allowed to participate in Canadian public  offerings , unless specifically mentioned.  So they are selling to the public via brokers. And they want to offload these as quickly as possible.  Their reward is the commission.


Also from the supplement::

"Under certain rules of the Canadian securities regulatory authorities and the Universal Market Integrity Rules for
Canadian Marketplaces of the Investment Industry Regulatory Organization of Canada (the "UMIR"), the
Underwriters may not, throughout the period of distribution, bid for or purchase Common Shares. These rules allow
certain exceptions to those prohibitions. The Underwriters may only avail themselves of those exceptions on the
condition that the bid or purchase not be for the purpose of creating actual or apparent active trading in, or raising the
price, of the Common Shares."
 
 
I appologize for beating this to death, but there have been several posts suggesting that there are some underhanded dealings associated with this PO.  While US offerings might somehow allow this, this is less likely in Canada due to trading restrictions such as the above.   Also the terms of a PO here are generally agreed to very quickly, partly to prevent particpants from taking early advangage of this info.
 
I might be wrong but that's how I see it.





<< Previous
Bullboard Posts
Next >>